课题基金 / 基金详情

Combined telomerase inhibition and drug screen as novel therapies for tumor initiating cells in pediatric nervous system tumors.

Combined telomerase inhibition and drug screen as novel therapies for tumor initiating cells in pediatric nervous system tumors.
结合端粒酶抑制和药物筛选作为小儿神经系统肿瘤肿瘤起始细胞的新疗法。
批准号：
192068
负责人：
Tabori Uri
金额：
$21.86万
依托单位：
Hospital for Sick Children (Toronto)
依托单位国家：
加拿大
项目类别：
Salary Programs
财政年份：
2009
资助国家：
加拿大
项目状态：
已结题
起止时间：
2009-09-01 至 2014-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=192068&lang=en
关键词：
Brain Tumors Neuroblastoma Telomerase Treatment Tumor Initiating Cells

项目摘要

项目成果

Tabori Uri的其他基金

相似基金

相关文献

中文摘要
翻译
肿瘤复发仍然是儿童癌症中最具破坏性的事件。尽管我们可以通过 我们目前的积极治疗，一些肿瘤往往复发，最终导致这些孩子屈服于他们的 疾病 在洛杉矶
英文摘要
Tumor recurrence is still the most devastating event in childhood cancer. Although we can achieve minimal disease with our current aggressive therapies, some tumors tend to recur, eventually causing these children to succumb to their disease. Over the la
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Uncovering the mechanism and impact of novel genetic and epigenetic promoter alterations on tissue-specific mismatch repair deficient cancers
Dissecting the origins and microenvironment of replication repair deficient hypermutant gliomas for novel immune based therapies
Biological and translational implications of replication repair deficiency and hypermutation in human cancer
Translating genomic discoveries to cure ultrahypermutant mismatch repair deficient brain tumors
海外基金